Keybanc Maintains Overweight on Monday.Com, Lowers Price Target to $270
Keybanc analyst Jackson Ader maintains Monday.Com (NASDAQ:MNDY) with a Overweight and lowers the price target from $280 to $270.
Teva Focus of FTC Investigation Over Inhaler Patents
Snowflake, Fox, Global-E Online Added to America's Conviction List: Goldman
Teva Pharmaceuticals Presents 4th Interim Analysis Of PEARL Migraine Prevention Study At EAN Congress; New Sub-Analysis Highlights Potential Negative Impact Of Treatment Pauses On Patient Outcomes
4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in HelsinkiNew sub-analysis of PEARL data highlights potential neg
Micron's Drop Leads Chips Lower Amid Profit Taking
Jefferies Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $23
Jefferies analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $19 to $23.
Teva Pharmaceutical Indus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 39.56% Jefferies $19 → $23 Maintains Buy 06/05/2024 27.43% Barclays $20 → $21 Maintains Overwei
Micron's AI Ramp From High-bandwidth Memory Is Just Starting: Analysts
Teva Expects No Impact From Israel Tax Authority Agreement On Its 2024 Financial Outlook, Which It Reaffirms
Teva Expects No Impact From Israel Tax Authority Agreement On Its 2024 Financial Outlook, Which It Reaffirms
Teva Pharmaceutical Industries Launches Authorized Generic Of Victoza In United States
Generic Victoza is the first-ever generic GLP-1 and supports increased demand for this category of therapies in the U.S. market.This launch adds to Teva's continued commitment to its complex generic m
Monday.com Drifts Lower Amid Hedgeye New Short Idea
Semi Stocks Undergo Upgrades, Price Target Hikes on AI Demand: B Riley
Applied Materials, Lam Research in Focus as Citi Expects Chip Spending to Rise
Camtek Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/20/2024 25.57% B. Riley Securities $110 → $150 Maintains Buy 06/07/2024 4.64% Needham $106 → $125 Maint
WalkMe Launches WalkMeX, The First Copilot With Contextual Guidance For Any Workflow Across All Applications, Enhancing Digital Adoption With AI
WalkMe Launches WalkMeX, The First Copilot With Contextual Guidance For Any Workflow Across All Applications, Enhancing Digital Adoption With AI
Pagaya Scores New Outperform Rating From KBW on Value to Lenders
Keefe, Bruyette & Woods Initiates Coverage On Pagaya Techs With Outperform Rating, Announces Price Target of $23
Keefe, Bruyette & Woods analyst Sanjay Sakhrani initiates coverage on Pagaya Techs (NASDAQ:PGY) with a Outperform rating and announces Price Target of $23.
14 Analysts Have This To Say About Monday.Com
In the last three months, 14 analysts have published ratings on Monday.Com (NASDAQ:MNDY), offering a diverse range of perspectives from bullish to bearish.The table below provides a concise overview o
Needham Reiterates Buy on Monday.Com, Maintains $250 Price Target
Needham analyst Scott Berg reiterates Monday.Com (NASDAQ:MNDY) with a Buy and maintains $250 price target.
Monday.Com Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/17/2024 11.11% Needham $250 → $250 Reiterates Buy → Buy 05/16/2024 2.22% DA Davidson $190 → $230 Mainta